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Inflammation is an important mediator of obesity-related complications such as the 
metabolic syndrome but its causes and mechanisms are unknown. As the complement 
system is a key mediator of inflammation, we studied whether it is activated in acquired 
obesity in subcutaneous adipose tissue (AT) and isolated adipocytes. We used a special 
study design of genetically matched controls of lean and heavy groups, rare monozygotic 
twin pairs discordant for body mass index (BMI) [n = 26, within-pair difference (Δ) in body 
mass index, BMI >3 kg/m2] with as much as 18 kg mean Δweight. Additionally, 14 BMI-
concordant (BMI <3 kg/m2) served as a reference group. The detailed measurements 
included body composition (DEXA), fat distribution (MRI), glucose, insulin, adipokines, 
C3a and SC5b-9 levels, and the expression of complement and insulin signaling path-
way-related genes in AT and adipocytes. In both AT and isolated adipocytes, the clas-
sical and alternative pathway genes were upregulated, and the terminal pathway genes 
downregulated in the heavier co-twins of the BMI-discordant pairs. The upregulated 
genes included C1q, C1s, C2, ficolin-1, factor H, receptors for C3a and C5a (C5aR1), 
and the iC3b receptor (CR3). While the terminal pathway components C5 and C6 were 
downregulated, its inhibitor clusterin was upregulated. Complement gene upregulation 
in AT and adipocytes correlated positively with adiposity and hyperinsulinemia and 
negatively with the expression of insulin signaling-related genes. Plasma C3a, but not 
SC5b-9, levels were elevated in the heavier co-twins. There were no differences between 
the co-twins in BMI-concordant pairs. Obesity is associated with increased expression 
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inTrODUcTiOn
The complement system has a pivotal role in obesity. While it is an 
important innate immune defense system against microbes and 
part of the body’s clearance system, it can also regulate the level 
of inflammation in the adipose tissue (AT) and have metabolic 
effects. Complement is a key innate sensor between viable and 
non-viable cells. It recognizes and opsonizes both foreign targets, 
like microbes, and exposed or damaged endogenous structures, 
and promotes their clearance by macrophages. Altogether, 
the complement system comprises up to 50 proteins that are 
synthesized by several tissues including the liver and various 
cell types of AT (adipocytes, macrophages, and vascular cells) 
(1–3). The complement proteins circulate in blood as activating 
or regulating components or act on cell membranes as receptors 
or protective molecules. Intriguingly, many links exist between 
the complement system and AT, but overall, the meaning and 
relevance of these links are mostly unclear.
The complement system can be activated through the classical, 
the lectin, or the alternative pathway. Specifically, the classical and 
the lectin pathways can recognize targets with specific pattern 
recognition molecules C1q, mannan-binding-lectin (MBL), and 
ficolins 1–3 (FCN1–3) (1–3). In contrast, the alternative pathway 
is continuously active and can amplify efficiently complement 
activation against non-self targets (2–4). All three pathways merge 
to activate the complement component C3, the most abundant 
complement factor in human blood plasma. Factor D (CFD, 
adipsin) is synthesized solely by adipocytes and its plasma levels 
are decreased in obesity (5). Factor D activates complement factor 
B (CFB) allowing the generation of the alternative pathway C3 
convertase C3bBb, which enzymatically cleaves new C3 molecules 
to C3a and C3b (1–3). Opsonization by C3b and by its inactivated 
product iC3b leads to the phagocytosis of target structures (1, 3). 
Activation of the early pathways of the complement system results 
in the generation of C5a, a potent anaphylatoxin, chemoattract-
ant, and leukocyte activator. Together with C3a, C5a can attract 
cytokine-producing macrophages and other leukocytes to the 
area of microbial invasion or tissue damage (1, 3). The completion 
of the cascade, the terminal pathway, leads to formation of the 
membrane attack complex (MAC, C5b-9) that allows sodium and 
calcium influx into cells. Membrane leakage will thus sequentially 
lead to strong metabolic activation, injury, and ultimately death 
of the target cell (4). Soluble complement inhibitors such as factor 
H (CFH), vitronectin and clusterin, and a group of membrane-
bound regulators [complement receptor 1 (CR1)/CD35, CRIg, 
MCP/CD46, DAF/CD55, and protectin/CD59] protect normal 
viable human cells against complement attack (3).
The complement system includes many proteins relevant to 
obesity, e.g., acylation-stimulating protein (ASP, C3a desArg) 
and adipsin (factor D). In addition, the activation-initiating 
complement proteins are related to adiponectin, which is an 
insulin-sensitizing and anti-inflammatory adipokine. Its plasma 
levels decrease in obesity (6). Adiponectin has structural simi-
larity to complement collectins C1q, MBL, surfactant proteins 
SP-A and SP-D, and FCN1–3. They are all multimers of triple-
helical structures, where each subchain has subunits composed 
of a globular and a collagen-like domain (7). Additionally, 
adiponectin participates in the clearance of dying cell material 
by macrophages via a calreticulin-mediated mechanism (8) and 
is an immune-modulator lowering tumor-necrosis factor-alpha 
(TNF-α)-levels (9). ASP is identical to the C3 activation product 
C3a desArg (10). In AT, ASP stimulates glucose uptake and free 
fatty acid storage postprandially (10). In the complement system, 
C3a desArg is mostly devoid of the anaphylatoxin or chemotactic 
activity of C3a. While C3a binds to the C3a receptor (C3aR), C3a 
desArg binds to the C5a receptor type 2 (C5aR2), which often 
mediates anti-inflammatory effects (11). C3aR expression has 
been shown to become upregulated in AT following a high-fat 
diet (12). It is intriguing that the C3a-C3aR (inflammation) and 
C3a desArg-C5aR2 (fat and glucose metabolism) interactions 
have such different effects.
During the progression of obesity, the adipocyte size increases, 
which associates with inflammation (13) and is linked to the devel-
opment of insulin resistance (14, 15). Plasma levels of C3, CFH, 
and CFB correlate positively with body mass index (BMI), waist 
circumference, triglycerides, and inflammatory parameters and 
negatively with insulin sensitivity and HDL cholesterol (16, 17). 
Complement components such as C3 and factor B are overpro-
duced by activated adipocytes in type 2 diabetes mellitus (T2DM) 
(18), and C3 is among the major determinants of metabolic 
syndrome in obese patients (19). Thus, the activated complement 
system is involved in the pathogenesis of cardiovascular disease 
(20). Upregulated complement gene expression by adipocytes 
from subcutaneous (sc) fat associates with insulin resistance (21, 
22). In a population-based cohort study, plasma levels of C3 were 
found to correlate positively with plasma insulin and glucose and 
to associate with the development of type 2 diabetes (23). Since 
complement is a main mediator of inflammation and clearance 
of non-viable tissue components, its role in obesity-related fat 
overload and metabolic disturbances merits more attention.
In humans, most of the studies on the complement system 
have been conducted in unrelated individuals without control 
for genetic variation. It is evident that genetic effects have a 
strong influence on both how complement activation is linked 
to inflammation (24) and on the weight gain (25) as well as for 
the developing complications thereafter. To exclude confounding 
due to shared genetic factors, we undertook a unique approach 
of analyzing complement gene expression in subcutaneous AT 
of genetically identical twins either concordant or discord-
ant for obesity. To exclude the effect of the immune-cell-rich 
of the early, but not late, complement pathway components and of key receptors. The 
twins with acquired obesity have therefore an inflated inflammatory activity in the AT. The 
results suggest that complement is likely involved in orchestrating clearance of apoptotic 
debris and inflammation in the AT.
Keywords: obesity, complement system, gene expression, twin study, monozygotic twins
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stroma-vascular fraction, we further analyzed the complement 
gene-expression profiles of isolated adipocytes. In addition to 
comparing the co-twins (effects of acquired obesity), we wanted 
to know whether complement gene expression is associated with 
adipocyte size, fat distribution (subcutaneous, intra-abdominal, 
and liver fat), systemic inflammation, systemic markers of insulin 
resistance, or the expression of insulin-signaling genes. This was 
explored separately in the AT and isolated adipocytes from the 
twin individuals. Finally, we stained AT biopsies immunohisto-
chemically to investigate the localization and intensity of C1q, the 
key activator of the classical pathway and of C3d, an indicator of 
prolonged complement activation. The results reveal an unprec-
edented coupling of the complement recognition molecules 
and early activation pathways with acquired obesity and related 
metabolic disturbances.
MaTerials anD MeThODs
Participants
The study population has been described in our previous studies 
(26–28). Briefly, the monozygotic (MZ) twin pairs (aged 22–36, 
54% women) were identified through the national population 
registry of Finland from 10 population-based birth cohorts 
(FinnTwin12 and FinnTwin16); 26 pairs being discordant for 
BMI, within-pair difference (Δ) in BMI >3 kg/m2 (mean Δweight 
18 kg), and 14 pairs concordant for BMI (ΔBMI <3 kg/m2) acting 
as their controls. All pairs were of European ancestry (Finnish), 
normotensive, and did not use any other medications than oral 
contraceptives, except for one obese co-twin with T2DM who 
used metformin and insulin, and one obese co-twin with inactive 
ulcerative colitis who used mesalazine and azathioprine. Twenty-
three subjects were habitual smokers. AT biopsies were available 
from all 80 subjects. mRNA was available for gene expression 
analyses in isolated adipocytes from 38 subjects (14  BMI-
discordant and 5 concordant pairs). The clinical characteristics 
within these twin pairs did not differ from the entire group of 80 
twins (Table S1 in Supplementary Material). The protocol was 
designed according to the principles of the Helsinki Declaration 
and all subjects gave their written informed consent. The Ethical 
Committee of the Helsinki University Central Hospital (DNRO 
270/13/03/01/2008) approved the protocol.
serum and Plasma analyses, Body 
composition, aT Biopsies, and adipocyte 
Morphology
Venous blood samples were obtained from all subjects after 
overnight fasting. EDTA plasma and serum samples were 
separated by centrifugation and stored at −80°C until the 
analyses of plasma glucose (spectrophotometric hexokinase and 
glucose-6-phosphate dehydrogenase assay, Roche Diagnostics, 
Basel, Switzerland), serum insulin (by time-resolved immuno-
fluorometric assay; Perkin Elmer, Waltham, MA, USA), plasma 
adiponectin and adipsin (DuoSet ELISA, R&D Systems Europe 
Ltd., Abingdon, UK), and serum high-sensitive C-reactive pro-
tein [hsCRP, Cobas CRP (Latex) HS, Roche Diagnostics] were 
performed. Plasma levels of fluid phase activation products of the 
complement system C3a (cleaved from C3) and SC5b-9 (soluble 
C5b-9) were determined by an enzyme-linked immunosorbent 
assay using MicroVue C3a Plus and C5b-9 Plus enzyme immuno-
assay kits (Quidel Corporation, San Diego, CA, USA) according 
to the manufacturer’s instructions. The absorbances were read at 
450 nm in a FluorStar Optima multidetection microplate reader 
(BMG Labtech GmbH, Ortenberg, Germany), and the concentra-
tions analyzed using Optima’s MARS 2.0 analysis software.
Body composition of the subjects was measured by Dual-
energy X-ray absorptiometry (Lunar Prodigy, Madison, WI, 
USA, software version 8.8). Fat percentage was calculated as fat 
mass/(fat mass + lean mass + bone mineral content) for the total 
body. Magnetic resonance imaging (MRI) was used for measur-
ing the volumes of abdominal subcutaneous and intra-abdominal 
fat, and magnetic resonance spectroscopy for measuring the liver 
fat percentage, as described earlier (29).
Adipose tissue biopsies were obtained from periumbilical 
subcutaneous fat using a surgical technique. RNA was prepared 
from frozen fat tissue (26). Adipocytes were isolated from the fat 
biopsy specimens treated with collagenase (28). The diameter of 
fat cells was measured under a light microscope. Fat-cell volume 
was calculated as described by Heinonen (13) assuming the 
adipocytes as spheres.
Transcriptomics analyses of aT and 
adipocytes
Transcriptomics experiments were performed with Affymetrix 
U133 Plus 2.0 chips. Raw gene expression data were pre-
processed with the GeneChip robust multiarray averaging 
(GCRMA) algorithm using BioConductor (30) in R and by 
using Brainarray custom CDF files for probe annotations (31). 
The data were validated with RT-qPCR as described (32). We 
selected 46 representative genes coding for components of the 
complement system for the expression analyses in the AT (Table 
S2 in Supplementary Material). The following genes from the 
insulin signaling pathway were used in analyses of the relation-
ships between complement system and insulin sensitivity in AT: 
insulin receptor (INSR), insulin-receptor substrate proteins 1–2 
(IRS1–2), and phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha (PIK3CA). The following complement 
factors were not included as they were not included in the array 
(C1QTNF4, C1QTNF6, C4, MBL, MASP-2) or were expressed at 
low levels (C8, C9, C4BP, C5aR2, and vitronectin) thereby lacking 
the inter-individual variation. GLUT4 gene was expressed at the 
lowest detection level, lacked inter-individual variation, and was 
therefore excluded from AT analyses.
Isolated adipocyte transcriptomics experiments were per-
formed with Affymetrix U133 Plus 2.0 chips similarly as for the 
AT samples. The expression levels of L-selectin (SELL) and C5aR2 
were not found from adipocyte transcripts. The same insulin 
signaling pathway-related genes than from AT and GLUT4 gene 
transcripts were analyzed.
immunohistochemical staining
We selected two BMI-discordant pairs and two BMI-concordant 
control twin pairs to visualize complement proteins in AT. Paraffin 
blocks of the AT were sectioned at 5 µm and two sections were 
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placed on each slide. One of the sections was used for staining 
with a primary and secondary antibody, while the other served as a 
mock control with buffer pipetted in place of the primary antibody.
First, a standard de-paraffination procedure was applied con-
sisting of 2× xylene (5′), followed by a series of ETOH (2′ each) in 
decreasing concentration and ending up in distilled water where 
samples slides were stored until the following day in preparation 
for staining. An antigen retrieval heat-treatment protocol followed, 
where section slides in EDTA buffer pH8.5 from Sigma (product# 
E1161, Sigma-Aldrich, St. Louis, MO, USA) + 0.05% Tween were 
brought to a boiling point in a microwave oven for 15′ followed by 
cooling in RT for 30′. The actual staining was carried out using 3× 
PBS washed heat-treated slides in a humidity chamber using Bright 
Vision plus Poly-HRP-Anti MS/RB/RT IgG REF DPVB55-HRP 
kit (Immunologic, Duiven, Netherlands). The grease pen limited 
section was subjected for Hydrogen Peroxide Block (UltraVision; 
Thermo Fisher Scientific, Waltham, MA, USA) incubation for 
10′, where after the manufacturer’s protocol for the staining kit 
was followed. The primary antibodies were diluted 1:1,000 in PBS 
(C1q and C3d both Rabbit pAb by DAKO, Glostrup, Denmark). 
The final step of the staining protocol was counterstaining by Gills 
Hematoxylin (2″) rinsing (10′) and finally series of ETOH (2′) 
treatments in increasing concentration finishing in 2× xylene (2′) 
and mounting by Depex. The slides were dried ON in a fume hood 
and stored in RT. Tissue histology was confirmed by standard HE 
staining for each tissue sample. Images of immunohistochemistry 
were collected using Olympus DP Manager (ver. 2.2.1.195) and 
Olympus DP Controller (ver. 2.2.1.227) image capture softwares 
with Olympus BX51 fluorescence microscope camera with 100×, 
200×, and 400× magnifications.
statistical analyses
The statistical analyses were performed using Stata statistical 
software (release 13.0; Stata Corporation). In addition to con-
trolling the effect of gender, the comparison of MZ co-twins 
(almost 100% identical at the DNA sequence level) allows 
controlling for genetic and shared environmental effects. Thus, 
any differences within twin pairs are by definition acquired (in 
our case, through BMI difference). Comparisons of the heavier 
vs. leaner co-twins’ clinical characteristics were analyzed by 
paired t-test (normally distributed) or Wilcoxon’s test (non-
normally distributed variables). Within-pair comparisons of 
the log2-transformed gene expression values were tested by 
paired t-test.
Student’s t-test was used for the co-twin comparison of 
the gene expression data. In addition, we assessed differences 
between genders, and smokers and non-smokers (individual 
twins) with Mann–Whitney U-test. Since some differences in 
the gene expression between smokers vs. non-smokers emerged, 
within-pair analyses were performed first among all twin pairs, 
whereafter habitual smokers were removed from the leaner vs. 
heavier comparison to assess whether the effect of smoking was 
confounding the results. As the differences in the gene expression 
between leaner and heavier co-twins still emerged to the same 
extent before and after exclusion of the smokers, we present the 
results from the whole cohort, with smokers included. Within-
pair analyses are by design adjusted for gender.
Mann–Whitney U-test was used to compare whether the 
characteristics of the leaner and the heavier co-twins in the BMI-
discordant pairs were the same in the whole group for whom AT 
was available and in those for whom data on adipocytes were 
available.
Using twins as individuals, the partial correlation analyses 
were performed to determine the relationships between AT/
adipocyte gene expression and adiposity measures, adipokines, 
and the insulin signaling gene expression. Since differences 
between genders and smokers vs. non-smokers emerged in 
individual twins’ gene expression, their effect was adjusted in 
correlation analyses. Logarithmic corrections were performed 
for log-normally distributed variables prior to the correlation 
analyses. Subsequently, the p values of partial correlates were 
adjusted for multiple testing by false-discovery rate (FDR) 
(Benjamini–Hochberg) (33).
resUlTs
study Population
Table  1 summarizes the subjects’ anthropometric and clinical 
characteristics (26–28). In brief, the heavier co-twins of the 
discordant pairs weighed on average 18 kg more, had 28% more 
total fat, 67% more subcutaneous fat, 200% more intra-abdom-
inal fat, and 300% more liver fat than their leaner counterparts. 
Accordingly, the adipocyte volumes of the heavier co-twins were 
57% larger than those of the lean co-twins. Furthermore, the 
heavier co-twins had higher plasma levels of insulin and adipsin, 
and lower adiponectin levels. BMI-concordant pair co-twins did 
not differ in any of the metabolic measures. They were also similar 
for all complement-related measures, which is why we report only 
the results from the discordant pairs.
The early complement Pathway 
components are Upregulated and c3 is 
More activated in heavier co-twins
Initially, we analyzed the effect of obesity on complement gene 
expression. In AT, 20 out of the altogether 46 complement genes 
expressed differently between the leaner and the heavier co-twins 
of the BMI-discordant pairs (Figure 1; Table S2 in Supplementary 
Material). In heavier co-twins of BMI-discordant pairs, the 
C1qA-C genes, those of the classical pathway activation initiat-
ing proteins, were upregulated. Accordingly, the genes for other 
classical pathway components: C1s, the key catalytic component 
of C1, the receptor for C1q (C1QR), C1r-like protease (C1RL), 
and C2 were upregulated. In contrast, the genes of FCN2, coding 
a protein recognizing acetylated carbohydrates in the lectin-
pathway, and C1QTNF7, a C1q and TNF-related protein (CTRP) 
family member, were downregulated in heavier co-twins.
The gene expression of the most abundant complement inhibi-
tor factor H (CFH) of the alternative pathway was upregulated 
in heavier co-twins compared to their leaner counterparts. 
Additionally, complement receptor of the immunoglobulin 
superfamily (CRIg/VSIG4) was upregulated. Thus, while the 
early classical pathway components were upregulated, the result 
suggests that complement activation would continue only up to 
FigUre 1 | The gene expression profile in subcutaneous adipose tissue within monozygotic body mass index-discordant twin pairs (heavier vs. 
leaner) differed in 20 out of 46 genes that code for components of the complement system. Genes that are upregulated in heavier co-twins are indicated 
with red and downregulated genes with blue.
TaBle 1 | The clinical characteristics of the monozygotic twin pairs.
BMi-discordant pairs BMi-concordant pairs (n = 14)
ΔBMi > 3 kg/m2, n = 26 pairs ΔBMi < 3 kg/m2, n = 14 pairs
Age (mean 
years ± SD)
30.4 ± 4.2
Sex 9 males/17 females 5 males/9 females
leaner
Mean ± se
heavier
Mean ± se p
leaner
Mean ± se
heavier
Mean ± se
N of current 
smokers
7 7 4 5
BMI 25.28 ± 0.89 31.25 ± 1.02 <0.0001 26.20 ± 0.92 27.65 ± 1.01
Fat percentage (%) 32.25 ± 1.81 41.14 ± 1.32 <0.0001 28.56 ± 2.57 29.89 ± 2.39
Adipocyte volume 
(μm3)a
371.9 ± 34.05 584.4 ± 49.55 <0.0001 364.7 ± 54.11 403.1 ± 46.87
Subcutaneous fat 
(cm3)
3,814 ± 416.9 6,359 ± 540.4 <0.0001 3,084 ± 351.7 3,428 ± 394.0
Intra-abdominal fat 
(cm3)
790.2 ± 179.0 1,644 ± 247.4 <0.0001 1,037 ± 173.2 1,093 ± 200.3
Liver fat% 1.12 ± 0.32 4.52 ± 1.00 <0.0001 1.99 ± 0.90 3.75 ± 1.75
fP-insulin (mU/L)b 4.93 ± 0.51 8.50 ± 1.21 <0.001 5.34 ± 1.13 5.61 ± 0.60
fP-glucose 
(mmol/L)b
5.13 ± 0.07 5.28 ± 0.11 0.174 5.27 ± 0.11 5.44 ± 0.15
hsCRP (mg/L) 2.56 ± 0.70 4.02 ± 1.14 0.065 1.25 ± 0.55 1.11 ± 0.19
Adipsin (pg/L)a 1,192 ± 49.05 1,309 ± 47.34 0.006 1,011 ± 121.7 1,047 ± 81.97
Adiponectin (ng/L) 3,842 ± 284.9 2,820 ± 232.2 0.0001 3,370 ± 539.9 2,603 ± 307.9
fP-C3a (ng/mL) 69.20 ± 4.16 77.82 ± 4.57 0.016 67.70 ± 9.24 61.45 ± 3.28
fP-SC5b-9 (ng/mL) 184.6 ± 10.28 193.64 ± 9.00 0.209 187.0 ± 15.13 184.3 ± 13.19
Wilcoxon signed-ranks test (leaner vs. heavier twin). Within-pair difference BMI >3 kg/m2 in discordant pairs (n = 26 pairs, 9 males), BMI <3 kg/m2 in concordant pairs (n = 14 pairs, 
5 males).
BMI, body mass index; fP, fasting plasma; hsCRP, high-sensitive C-reactive protein; C3a, complement component 3a; SC5b-9, the soluble terminal complement complex.
an = 8 concordant pairs.
b25 discordant pairs.
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the C3/C5 convertase level because of upregulation of the main 
inhibitory control factor CFH. In accordance, the plasma levels 
of C3a and adipsin were higher in the heavier, but the levels of 
SC5b-9, a marker of terminal pathway activation, were similar 
between the heavier and the leaner co-twins of BMI-discordant 
pairs (Table  1). This indicates that complement activation in 
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obese individuals indeed occurred up to the C3 activation level 
but not beyond that to the terminal pathway.
Upregulated gene expression of 
complement receptors and complement 
inhibitors and Downregulation of the 
Terminal Pathway in aT of heavier  
co-twins
The genes for C3aR1 and C5aR1, important complement 
receptors found, e.g., on the surfaces of macrophages and 
other immune cells, were upregulated in heavier co-twins’ AT 
(Figure 1; Table S2 in Supplementary Material). Furthermore, 
the heavier co-twins had an upregulated gene expression of 
components of the beta-integrin CD11b/CD18, the major 
phagocytic receptor (CR3) for particles coated with iC3b. 
The genes of the terminal pathway components C5 and C6 
were downregulated, whereas the gene of the soluble terminal 
complement complex binding clusterin (CLU) was strongly 
upregulated in heavier co-twins. This indicates that the ter-
minal pathway is suppressed in obese individuals, whereas 
the receptors for early activation pathway components are 
upregulated to mediate their functional effects.
complement gene expression Profiles of 
isolated adipocytes Differ between BMi-
Discordant co-twins
As AT is a mixture of adipocytes, immune cells, vasculature, 
and the connective tissue stroma, we next wanted to study the 
expression profiles of complement genes in isolated adipocytes. 
The levels of 25 out of 45 complement genes expressed by isolated 
adipocytes differed between heavier and leaner co-twins of the 
BMI-discordant pairs (Table S3 in Supplementary Material). 
Similar to AT, in the adipocytes, the complement genes of the 
classical and alternative pathways were upregulated and genes of 
the terminal pathway were downregulated in heavier co-twins. 
However, a few differences in adipocytes compared to the AT 
expression profile were observed: ADIPOQ, FCN1, CALR, 
and CFH gene expressions were similar between co-twins of 
BMI-discordant pairs, but the gene expressions of C1-inhibitor 
(SERPING1), CD93, C3, CFB, C5AR1, and the MAC-inhibiting 
molecule CD59 (protectin) were upregulated in heavier co-
twins. Again, the gene expression profiles of isolated adipocytes 
of the co-twins of BMI-concordant pairs were similar (data not 
shown).
adiposity Measures associate with 
Upregulated expression of genes in the 
classical and the alternative Pathways 
and Downregulation of genes in the 
Terminal Pathway-related genes
The correlations between adiposity measures, metabolism, 
inflammation, and complement gene expression profiles in AT 
and adipocyte transcripts are presented as heatmaps in Figure 2. 
Table S4 in Supplementary Material shows the corresponding 
r values and p values after correction for multiple parameters.
In AT samples, the complement gene expression levels cor-
related significantly with BMI (18 out of 46 genes), adipocyte 
volume (23/46), sc fat (22/46), intra-abdominal fat (29/46), liver 
fat (22/47), hsCRP (28/46), and plasma adipsin (18/46) levels. The 
correlations of adiposity measures were positive for genes of the 
classical and the alternative pathway components and negative 
for the terminal pathway components C5 and C6. Furthermore, 
SERPING1 and the C1q homologs C1QTNF7 and FCN2 cor-
related negatively with adiposity measures.
The complement gene expression of isolated adipocytes cor-
related most significantly with intra-abdominal fat (24 out of 
45 genes), sc and liver fat (13/45 for both), and hsCRP (23/45). 
The correlations were positive except for C1QTNF7, FCN2, C5, 
and C6.
Upregulation of the classical and 
alternative Pathway components 
associates with hyperinsulinemia and 
Downregulated insulin signaling route
Next, we examined whether the complement gene expression in 
AT and adipocytes was associated with plasma insulin and expres-
sion of genes along the insulin signaling route (INSR, IRS1–2, and 
PIK3CA in both AT and adipocytes, and additionally GLUT4 in 
adipocytes) (Figure 2; Table S4 in Supplementary Material for the 
corresponding r values and p values after correction for multiple 
parameters). A strong inverse correlation between the classical 
and the alternative pathway and insulin signaling route gene 
expression was found both in AT and adipocytes. Plasma insulin 
correlated positively with the expression of 25/46 complement 
genes in AT but only with CR1 gene expression of adipocytes. 
C6, C1QTNF7, FCN2, and FCN3 expression in AT correlated 
negatively with plasma insulin.
Visualization of complement Proteins  
in aT
Finally, we investigated the location of two complement proteins 
by immunohistochemistry from paraffin-embedded AT samples. 
Two complement components were stained: C1q indicating ini-
tiation of the classical pathway and C3d representing the remnant 
of C3b deposition typically observed in prolonged complement 
activation (examples shown in Figures  3A–D). Crown-like 
structures representing tissue macrophages around apoptotic 
adipocytes were observed in both leaner and heavier co-twins 
of the BMI-discordant pairs, even though they seemed to be 
more abundant in heavier co-twins’ AT. C1q stained abundantly 
on cell membranes and intracellularly in the apoptotic cells. 
Occasionally, intense nuclear staining of adipocytes occurred 
adjacent but independently of the crown-like structures. C3d 
stained faintly but evenly on the cell membranes – most likely on 
the basal surface of the stain-positive cells. Additionally, intracel-
lular granular aggregates staining intensively for C3d emerged in 
the crown-like structures, but also in some individual adipocytes.
DiscUssiOn
The present study illustrates how obesity can induce a coordinated 
and synchronized regulation of the complement system genes. 
FigUre 2 | The correlations between the complement gene expression and the obesity measures, inflammation, and insulin signaling-related genes 
in monozygotic (MZ) twin individuals taking into account the effect of gender and smoking. MZ twin individuals, n = 80; cell volume, n = 65; plasma 
adipsin, n = 70; plasma adiponectin, n = 80; insulin, n = 80; adipocyte gene transcripts, n = 38. *Statistical significance, p < 0.05, **p < 0.001, ***p < 0.0001 after 
multiple correction (false-discovery rate, Benjamini–Hochberg). BMI, Body mass index; Cell volume, adipocyte volume; Sc fat, subcutaneous fat; Ia fat, intra-
abdominal fat; Liver fat, liver fat percentage; CRP, high sensitive C-reactive protein; INSR, insulin receptor; IRS1-2, insulin receptor substrate 1-2; PIK3CA, 
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha; GLUT4, glucose transporter type 4.
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The expression of a broad spectrum of complement genes was 
analyzed in AT and isolated adipocytes in young adult MZ twins, 
nearly all of whom were free from obesity-related co-morbidities. 
Within BMI-concordant pairs, the co-twins’ gene-expression 
profiles were similar suggesting that the overall expression levels 
of complement genes are largely familial, and probably controlled 
by genetic or shared environmental factors.
Several interesting differences emerged within BMI-discordant 
MZ twins: the expression of genes of complement activating and 
regulating components within AT and isolated adipocytes was 
clearly different in heavier compared with their leaner co-twins. 
Most of the differences in the co-twins remained in isolated adi-
pocytes’ transcripts even after separating them from the immune 
cell-rich stroma-vascular fraction. The main findings were the 
following: in heavier co-twins, the classical and the alternative 
pathway complement gene expressions were mostly upregulated. 
These pathways mediate all main physiological functions of the 
complement system. They recognize microbes, antigen–antibody 
complexes, materials from injured cells and tissues, and other 
targets. Complement activation products promote opsonization, 
chemotaxis, leukocyte recruitment, activation, and phagocytosis. 
These effects are mediated by specific receptors that, accordingly, 
were also upregulated. In line with these results, the plasma levels 
of C3a, a marker of the activation of early complement pathways, 
were elevated in the heavier co-twins. Instead, the levels of the 
soluble terminal pathway complement complex SC5b-9 remained 
unchanged. This matches with the gene expression data, where the 
terminal pathway components C5 and C6 were downregulated, 
while the inhibitor clusterin was upregulated. When combined, 
the results demonstrate that complement is involved in obesity-
related inflammation but not in direct MAC-mediated tissue 
destruction.
Our results demonstrating the effects of excess body weight in 
young adults are in accordance with previous studies reporting 
upregulated complement gene-expression levels in AT in obese, 
dyslipidemic, and diabetic subjects (4, 21, 23). We made several 
interesting new observations on upregulated complement genes 
in the heavier co-twins’ AT and on their association with obesity 
and metabolic disturbances. All the three sub-chains of C1q, 
A-C, were upregulated in obesity. They constitute C1q, a mul-
timeric protein that binds to antigen–antibody complexes and 
to many types of cellular structures, which are either exposed or 
released during cellular damage (phospholipids, mitochondria, 
etc.). Bound C1q is subsequently recognized by macrophage 
receptors that mediate phagocytosis of the targets (34, 35). A 
novel observation was that the C1r-related protein C1RL gene 
expression increases in acquired obesity and associates with 
accumulation of intra-abdominal fat. C1QTNF7, a member of 
the CTRP family and closely related to C1q, was downregulated 
in heavier co-twins. Interestingly, C1QTNF7 responds to caloric 
restriction in mice and therefore has a potential role in the control 
of the energy balance (36). Furthermore, calreticulin, a C1QR, 
showed upregulated gene expression in the heavier co-twins 
and correlated positively with hyperinsulinemia and negatively 
with the genes involved in the insulin signaling route. The results 
from Jalali (37) showing the association between INSR density 
and calreticulin, and Lo (5) demonstrating that calreticulin 
correlates positively with pancreatic insulin secretion increasing 
adipsin, support a potential role for calreticulin in the regulation 
of glucose metabolism.
Another novel observation was that genes of the C3 convertase 
inhibitor CFH and the alternative pathway suppressing VSIG4 
(CRIg), a member of the complement receptor immunoglobu-
lin superfamily, were upregulated in heavier co-twins. VSIG4 
FigUre 3 | immunohistochemistry stain of subcutaneous adipose tissue (aT). (a) Leaner twin AT stained with C1q (400×); (B) leaner twin AT stained with 
C3d (400×); (c) heavier twin AT stained with C1q (400×); (D) heavier twin AT stained with C3d (400×); the arrows point out crown-like structures.
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correlated strongly positively with overall and intra-abdominal 
fat and with plasma insulin levels. VSIG4 inhibits T-cell prolif-
eration, clears complement-opsonized particles, and binds to 
C3b (38). VSIG4 is known as a potential biomarker of severe 
preeclampsia (39). Therefore, despite the upregulation of comple-
ment activating components C3 and CFB in obese subjects, the 
concomitant upregulation of the alternative pathway regulatory 
genes indicates that an excessive activation and amplification of 
this pathway can be suppressed in AT. Alternative pathway activa-
tion occurs in a regulated manner generating C3a, and possibly 
C5a (by the C3/C5 convertases), as well as the C3b inactivation 
product iC3b (by CFH and CFI), but remains at a reasonable level 
to prevent transmission of amplification to the terminal pathway.
The levels of SC5b-9, a soluble equivalent of MAC with only 
one C9 remained unchanged in the heavier co-twins. In the 
heavier co-twins, upregulation of complement inhibitors and 
downregulation of the expression of C5 and C6 indicate that 
excessive early pathway activation in obesity does not translate 
into the terminal pathway. Thus, complement activation is related 
more to increased opsonophagocytic and anaphylatoxic capacity 
than to direct cell damaging activity by MAC. Clusterin gene 
expression showed overall the most significant differences within 
BMI-discordant co-twins and the strongest positive correlation 
between obesity measures, liver fat, hsCRP, hyperinsulinemia, and 
adipsin and negative correlation with insulin signaling route gene 
expression in twin individuals. Our results are in line with Won 
et al. (40), who showed that subjects with metabolic syndrome 
have elevated levels of clusterin in plasma. In fact, clusterin is a 
multifunctional molecule, whose activities extend beyond those 
in the complement system. In addition to being an inhibitor of 
MAC, it can cluster cells and act as an apolipoprotein, hence the 
alternative names SP40, 40, and ApoJ (41).
Clusterin suppresses the terminal pathway by inhibiting forma-
tion of the complement MAC, composed of components C5b, C6, 
C7, C8, and multiple C9 molecules (42). Clusterin prevents inser-
tion of intermediate terminal pathway complexes (C5b-7, C5b-8, 
and C5b-9) to membranes. During this process, it incorporates 
into the complexes. Increased expression of clusterin may thus 
be related to the inhibition of excess complement-mediated cell 
damage that is initiated by increased expression of early pathway 
components, ischemia, or the release of complement-activating 
lipids from adipocytes. In addition, by being an apolipoprotein 
and scavenger for hydrophobic molecules, clusterin could also 
directly bind to hydrophobic particles released from fat tissue and 
play a role in their removal.
Adipocyte cell volume was associated with complement gene 
expression in the AT similarly as the overall obesity measures. 
A positive association emerged for the adipocyte size with the 
classical and the alternative pathway and a negative one with 
the terminal pathway-related genes. The adipocytes undergo 
changes in their cell membranes in the development of the 
obese state and potentially this alters the structural conforma-
tion and type of surface membrane molecules they express (43). 
Large adipocytes act as antigen-presenting cells by expressing 
major histocompatibility class II molecules and take part in 
the generation of pro-inflammatory immune response (43). 
Contrasting and potentially generating a balancing response, 
C1q, a structural homolog of adiponectin, promotes anti-
inflammatory macrophage polarization (35, 44, 45). Thus, 
upregulated C1q expression in AT may be reactive and signal a 
tissue defense mechanism and local immune cell infiltration. It is 
noteworthy that multiple C1q homologs, adiponectin, FCN1–2, 
and C1qTNF7 showed changes in obesity. This suggests their 
involvement in an adipocyte-macrophage collaboration process, 
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possibly related to debris clearance. As we were limited by sample 
availability, the immunohistochemical stains did not provide 
quantifiable data. In the descriptive analyses, a pattern emerged, 
where C1q stain appeared more intense and widespread in the 
obese twins than their lean co-twins. The pattern of C1q may 
reflect ongoing phagocytosis (e.g., of necrotic or apoptotic adi-
pocytes) and/or increased inflammation in the heavier co-twins 
albeit being present also in the leaner.
The associations between intra-abdominal fat, liver fat, crp, 
and the genes of the insulin signaling route and differences in 
most of expression levels of the complement genes remained 
significant in adipocyte transcripts after the contribution of the 
stroma-vascular fraction was excluded. In contrast, the role of 
the stroma may be significant when interpreting the correlations 
between BMI, sc fat. adipocyte cell size, sc fat and insulin. The 
correlations between complement gene expressions and these 
measures were weaker in adipocyte transcripts than in AT. 
Indeed, it is not the obesity per se but the central adiposity and 
ectopic fat in liver that are related to alterations in the comple-
ment gene expression.
Our study of MZ twin pairs is unique in that genetic factors as 
causes for differences in within-pair comparisons can be excluded. 
Esparza-Gordillo (24) estimated that 62% of the complement 
factor H (CFH) phenotypic variation is due to additive genetic 
effects. Nestvold (46) showed that the complement system is reac-
tive to environmental factors as levels of C3 and C4 dropped after 
weight loss. The observed differences within weight-discordant 
pairs emphasize the role of non-genetic influences, including 
environmental factors and acquired obesity in regulating the 
expression and activation of the complement system. Finding 
healthy young adult MZ pairs with significant discordance 
in body weight is extremely difficult, as body weight is tightly 
genetically regulated (47). The experiences and exposures of MZ 
twins are often very similar through childhood and adolescence 
and begin to differ only after moving out of their parental home 
and into individual personal and occupational trajectories (48). 
Therefore, although our sample size is relatively small, the study 
represents perhaps the best-controlled study design available 
in humans because of the full match for genes, age, gender, and 
intrauterine and childhood environment between the lean and 
heavy groups.
The limitations of our study include that due to small biopsy 
materials from the volunteers, we lack protein or functional data 
on the AT samples. However, we documented that circulating 
C3a protein levels were elevated in obesity, potentially indicating 
complement activation also at the whole-body level. Our gene-
expression analyses also lacked the data for some components 
of complement cascade such as the pattern recognition protein 
MBL, C4, C8, and C9. The study setting does not allow direct 
causal conclusions, but indicates that the observed differences 
within BMI-discordant co-twins are not due to confounding 
genetic effects.
In summary, our study shows that characteristic to comple-
ment activation in obese AT is upregulation of the classical and 
the alternative pathway sensors and receptors and downregula-
tion of the terminal pathway. In the AT, the activating factors 
and the receptors were upregulated simultaneously indicating 
preparedness for controlled phagocytosis. In addition to the 
pattern-recognition molecules needed for phagocytic activity, 
similar gene-expression patterns also emerged in isolated adipo-
cytes, which indicates their independent role in inducing changes 
in the complement system in the obese AT. Overall, the study 
reveals the close relationship between the complement system 
and AT in obesity. These results pave the way for further analyses 
of the complement-mediated regulation of inflammation and 
lipid clearance and its potential role leading to adverse metabolic 
complications in obesity.
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